Relation between iridopathy and retinopathy in diabetes

Francesco Bandello, Rosario Brancato, Rosangela Lattanzio, Marcello Galdini, Bruno Falcomata

Abstract
In order to assess the relation between diabetic iridopathy (DI) and retinopathy (DR), 225 eyes of 117 diabetics with clear media were evaluated. Each patient underwent iris and retinal fluorescein angiography, which was used to classify DI and DR. DI was classified as: absence of DI; non-proliferative DI; proliferative DI; neovascular glaucoma. DR was classified as: absence of DR; background DR; pre-proliferative DR; proliferative DR. The sensitivity of iris fluorescein angiography in assessing DI was 44-55%, the specificity 88%, the positive predictive value 92-8%, and the negative value 31-2%. In pre-proliferative and proliferative DR, fluoroiridographic detection of iris neovessels gave a sensitivity of 56% and a specificity of 100%. The positive predictive value was 100% and the negative value 6%. In conclusion, iris fluorescein angiography yields valuable information on DR and is a helpful basis for avoiding complications when scheduling eyes with dioptric media opacities for surgery. (Br J Ophthalmol 1994; 78: 542–545)

In diabetic patients the whole vascular system of the eye can be affected by microangiopathy; iridopathy and retinopathy are two of its most severe manifestations. The presence of advanced forms of diabetic retinopathy (DR) and/or diabetic iridopathy (DI) contraindicates many ophthalmic surgical procedures. The high level of neovascular complications in diabetic patients is well known, as is the higher risk of neovascular glaucoma following vitrectomy and cataract extraction, particularly intracapsular extraction. This means that abnormalities of the iris and retina must be assessed carefully before any surgical manipulation in order to avoid complications. Sometimes, however, DR is not detectable because of opacity of the dioptric media. In these cases, iris fluorescein angiography is the only way to evaluate diabetic microangiopathy and hence to make an indirect assessment of the DR. To date, the relation between iridopathy and retinopathy in diabetes has not been clearly elucidated. The aim of this study was to assess the relation between detectable iris and retinal lesions in diabetic patients without dioptric media opacities in order to answer the following questions: (1) When DI is absent, what type of DR will be present? (2) When non-proliferative DI is present, what type of retinopathy exists with it? And therefore: (4) Is DI an indicator of DR?

Materials and methods
Patients were recruited from among all those who visited our outpatient department between January and April 1991. The inclusion criteria were diabetes mellitus type I or type II. The exclusion criteria were: opacities of the dioptric media, causing difficulties in retinal fluorescein angiography; other ocular diseases; topical myotic therapy; previous laser treatment; previous ocular surgery.

A total of 225 eyes of 117 patients were included in the study. Nine eyes were excluded; three because of opacities of the dioptric media, two because of retinal vein occlusion, and four because of previous laser treatment. The clinical characteristics of all patients included in the study are summarised in Table 1. They all provided informed consent for entry to the trial. All patients underwent a complete ocular examination, a fluorescein angiography of the iris, and stereoscopic colour fundus photographs of seven standard fields. Iris fluorescein angiography was performed using a modified standard Zeiss photo slit-lamp, with a dual filter system (excitation filter and barrier filter) and the

Table 1 Clinical characteristics of patients included in the study

<table>
<thead>
<tr>
<th>Age (years) (SD)</th>
<th>58-0 (13-9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>53 (45-2%) Males</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>48 (41%) Insulin dependent</td>
</tr>
<tr>
<td>Type</td>
<td>Duration (years) (SD)</td>
</tr>
<tr>
<td>DR</td>
<td>Visual acuity (SD)</td>
</tr>
</tbody>
</table>

Figure 1 Iris fluoresceinangiographic picture of a diabetic patient without iridopathy; the morphology and permeability of iris vessels are within the normal range, and no dye leakage is present even though this is a late phase angiogram.
assessed by colour fundus photographs. The iris and retinal photographs were then matched.

DI was classified as follows:

**grade 0**: absence of DI (no DI) (Fig 1); fluorescein leakage is absent in late phases too;

**grade 1**: non-proliferative DI (NPDI), with dilated pupillary and stromal capillaries which let the dye leak through, giving rise to slight, short lasting fluorescence. Once the dye bolus has passed through, the hyperfluorescence tends to diminish and disappear, a diffuse veil remaining in the anterior chamber (Fig 2);

**grade 2**: proliferative DI (PDI), with new vessels at the pupillary margin and/or stroma, filling rapidly with dye and leaking equally promptly and diffusely (Fig 3);

**grade 3**: neovascular glaucoma (NVG), with newly formed fibrovascular tissue on the iris surface and at the iridocorneal angle, associated with intraocular hypertension.

Pupillary margin leakage was considered physiological in patients aged over 50 years25,26; therefore, eyes with age-related pupillary margin leakage only were classified in the group without DI (Fig 4).

Figures 1-4 were used as the standard angiograms against which all eyes were compared in order to minimise individual variations within each classification.

DR was classified as follows:

**grade 0**: absence of DR (no DR), corresponding to level 1 of the abbreviated version of the Modified Airlie House classification23;

**grade 1**: background DR (BDR), comprising levels 2, 3, and 4;

**grade 2**: pre-proliferative DR (PPDR), corresponding to level 5;

**grade 3**: proliferative DR (PDR), equivalent to level 6.

Results

Table 2 compares the DI and DR group findings. In the 141 eyes without DI, 31% had no DR, 34% had BDR, 21% had PPDR, and 14% had PDR (question 1).

In the 14 eyes with NPDI almost half had no accompanying DR, 15% had BDR, 21% had PPDR, and the remaining 21% had PDR (question 2). The mean age distribution of the patients with NPDI was: (1) patients without DR: 52.8 years (SD 15.4); (2) patients with BDR: 57.4 years (SD 11.7); (3) patients with PPDR: 45.4 years (SD 13.2); and patients with PDR: 62.5 years (SD 21.7).

The 68 eyes with PDI all had severe retinopathy; it was pre-proliferative in one third and

---

### Table 2: Relation (%) between diabetic iridopathy (DI) groups and diabetic retinopathy (DR) groups

<table>
<thead>
<tr>
<th>No DI</th>
<th>NPDI</th>
<th>PDI</th>
<th>PPDR</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No DR</td>
<td>44 (31)</td>
<td>6 (45)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>BDR</td>
<td>48 (34)</td>
<td>2 (15)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PPD</td>
<td>29 (21)</td>
<td>3 (21)</td>
<td>25 (37)</td>
<td>0</td>
</tr>
<tr>
<td>PDR</td>
<td>20 (14)</td>
<td>3 (21)</td>
<td>43 (63)</td>
<td>2 (100)</td>
</tr>
<tr>
<td>Total</td>
<td>141</td>
<td>14</td>
<td>68</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No DR</th>
<th>absence of DR</th>
<th>BDR</th>
<th>background DR</th>
<th>PPDR</th>
<th>pre-proliferative DR</th>
<th>PDR</th>
<th>proliferative DR</th>
</tr>
</thead>
<tbody>
<tr>
<td>No DI</td>
<td>absence of DI</td>
<td>NPDI</td>
<td>non-proliferative DI</td>
<td>PDI</td>
<td>proliferative DI</td>
<td>NVG</td>
<td>neovascular glaucoma</td>
</tr>
</tbody>
</table>
Table 3  Comparison (%) of mild and serious forms of diabetic iridopathy (DI) and diabetic retinopathy (DR)

<table>
<thead>
<tr>
<th>Condition</th>
<th>No DI/NPDI</th>
<th>PDI/NVG</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No DR/BDR</td>
<td>100 (65)</td>
<td>0</td>
<td>100 (44)</td>
</tr>
<tr>
<td>PPDR/PDR</td>
<td>55 (35)</td>
<td>70 (100)</td>
<td>125 (56)</td>
</tr>
<tr>
<td>Total</td>
<td>155</td>
<td>70</td>
<td>225</td>
</tr>
</tbody>
</table>

No DR = absence of DR; BDR = background DR; PPDR = pre-proliferative DR; PDR = proliferative DR. No DI = absence of DI; NPDI = non-proliferative DI; PDI = proliferative DI; NVG = neovascular glaucoma.

proliferative in two thirds. The two cases of NVG both had concomitant PDR (question 3). In answer to question 4: Is DI an indicator of DR?, and thus to assess whether fluoroiridographic detection of DI is useful as an indirect assessment of DR, we considered:

- patients without DI and without DR as true negative;
- patients with DI and DR as true positive;
- patients without DI but with DR in any form as false negative;
- patients with DI in any form but with no fluoroorangiographic retinal lesions as false positive.

The specificity of fluoroorangiographic detection of DI in assessing DR turned out to be 88% and the sensitivity was 44.5%. The positive predictive value was 92.8%, the negative value was 31.2%.

In clinical practice it is helpful to detect serious forms of DR before scheduling cataract or retinovitreal surgery, in order to avoid complications. Table 3 summarises the picture we obtained when we correlated the presence of absence of serious DI (PDI and NVG) to the presence or absence of serious DR (PPDR and PDR).

Fluoroiridographic detection of iris neovessels turned out to have a specificity of 100% in assessing the serious forms of DR, and its sensitivity was 56%. The positive predictive value was 100% and the negative value 65%. In the case list, therefore, all the eyes with iris neovessels had PPDR or PDR, and 56% of the eyes with serious DR had iris neovessels.

Discussion

In diabetic patients it is important to be able to establish what type of retinopathy is behind a cataract or other type of diabetic media opacity, as serious complications can develop in a patient operated on without this knowledge. In some time now we have been using iris fluorescein angiography in the preoperative evaluation of diabetic patients, as we are led to believe that the degree of iridopathy present is indicative of the degree of retinal microangiopathy. Many studies have been published on iris fluorescein angiography in diabetic patients, but only one other study (by Algvere and Kornacki) evaluates the relation between DR and DI, using both iris and retinal fluorooriography. Our results basically confirm those of Algvere and Kornacki, even though they used a different method of classification of DI and DR.

Iris fluorescein angiography was certainly a helpful diagnostic tool, because the detection of DI in any form (NPDI, PDI, NVG) was associated with DR in all but 7% of the cases in our study. Furthermore, each time proliferative iridopathy was detected, the patient also had serious pre-proliferative or proliferative DR. Clinically therefore, when iris neovascularisation is detected in an eye in which it is impossible to evaluate retinopathy because of opacity in the dioptric media, concomitant serious retinopathy must be presumed, and great care must be taken in the management of the eye. Before cataract extraction or vitrectomy, cryocoagulation or transscleral photocoagulation must be done to destroy the non-perfused peripheral areas of the retina. Sometimes endophotocoagulation carried out in the course of vitrectomy, or photocoagulation done in the days immediately after cataract extraction can produce just as good results.

Moreover, iris fluorescein angiography should not be seen as an invasive diagnostic procedure which is without value. It would be a mistake to think that even a well carried out biomicroscopic examination can provide the same level of diagnostic information. In a study we carried out on 114 eyes of 63 diabetic patients we used iris fluorescein angiography as the standard against which to test the ability of iris biomicroscopy to demonstrate DI. The sensitivity of biomicroscopy in detecting DI turned out to be 57%, while the specificity was 94%. The positive predictive value was 93% and the negative predictive value 50%. Our study proved that biomicroscopy can judge accurately when DI is absent; when it is present, however, there is a high probability that biomicroscopy will be less precise in the detection of iris lesions.

In the present study, in patients without DI, on the other hand, the iris fluorescein angiographic information seems less useful. Sixty nine per cent of our cases had DR but no DI; 35% were pre-proliferative or proliferative forms of DR. This proportion of false negatives shows that great care is required in the management of the diabetic patient, in whom the fundus can only be explored by ultrasound (because of cataract or vitreous haemorrhage), even if the iris vessels appear normal when examined angiographically. In these patients, when retinal ischaemia is detected, either endophotocoagulation during vitrectomy, or transpupillary retinal photocoagulation after cataract extraction, should be considered mandatory procedures.

So, in answer to our question as to whether DI is an indicator of DR, we can conclude from this study that iris angiography yields valuable information on diabetic ocular microangiopathy, since the presence of DI (especially if serious) is significantly related to the presence of DR in varying degrees of severity. Using iris angiography we were able to detect the eyes with the most serious forms of DR — that is, those most likely to present major complications following surgery. Our results are clinically important, as they enable us to consider the presence of retinopathy even when we cannot explore the fundus because of a cataract or vitreous haemorrhage. Fluorooriography thus appears to be a useful tool when scheduling such eyes for surgery.

However, although the presence of diabetic iridopathy, especially in its severe forms,
indicates the presence of diabetic retinopathy, the absence of diabetic iridopathy certainly does not exclude the presence of diabetic retinopathy.


Relation between iridopathy and retinopathy in diabetes.

F Bandello, R Brancato, R Lattanzio, M Galdini and B Falcomatà

Br J Ophthalmol 1994 78: 542-545
doi: 10.1136/bjo.78.7.542

Updated information and services can be found at:
http://bjo.bmj.com/content/78/7/542

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/